ARVN Q1 2024 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-22.2% YoY

Gross Profit

$24M93.3% margin

Operating Income

-$83M-329.2% margin

Net Income

-$69M-274.3% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+158.7%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$98M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$603M

Stockholders' Equity

$610M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$33M	-22.2%
Gross Profit	$24M	$31M	-23.4%
Operating Income	-$83M	-$88M	+5.0%
Net Income	-$69M	-$82M	+15.3%